CIs of GVHD after matched-pair analysis in subgroups of patients
| . | 100-d grade II-IV aGVHD (95% CI) . | 100-d grade III-IV aGVHD (95% CI) . | 2y-cGVHD, any grade (95% CI) . | 2y-cGVHD, extensive (95% CI) . |
|---|---|---|---|---|
| Patients receiving cyclosporine + mycophenolate mofetil | ||||
| PTCY | 27 (14-42) | 8 (2-19) | 28 (13-46) | 19 (5-40) |
| ATG | 36 (26-47) | 22 (14-32) | 31 (21-42) | 21 (12-31) |
| P | .23 | .07 | .42 | .48 |
| Patients in CR at time of transplant | ||||
| PTCY | 32 (21-43) | 8 (3-16) | 45 (28-60) | 21 (10-34) |
| ATG | 30 (22-38) | 16 (10-24) | 37 (28-46) | 23 (15-32) |
| P | .98 | .1 | .71 | .74 |
| Patients receiving PB as stem cell source | ||||
| PTCY | 29 (20-39) | 8 (4-16) | 38 (24-51) | 19 (10-31) |
| ATG | 32 (25-39) | 18 (13-25) | 36 (28-44) | 20 (14-28) |
| P | .41 | .04 | .61 | .72 |
| . | 100-d grade II-IV aGVHD (95% CI) . | 100-d grade III-IV aGVHD (95% CI) . | 2y-cGVHD, any grade (95% CI) . | 2y-cGVHD, extensive (95% CI) . |
|---|---|---|---|---|
| Patients receiving cyclosporine + mycophenolate mofetil | ||||
| PTCY | 27 (14-42) | 8 (2-19) | 28 (13-46) | 19 (5-40) |
| ATG | 36 (26-47) | 22 (14-32) | 31 (21-42) | 21 (12-31) |
| P | .23 | .07 | .42 | .48 |
| Patients in CR at time of transplant | ||||
| PTCY | 32 (21-43) | 8 (3-16) | 45 (28-60) | 21 (10-34) |
| ATG | 30 (22-38) | 16 (10-24) | 37 (28-46) | 23 (15-32) |
| P | .98 | .1 | .71 | .74 |
| Patients receiving PB as stem cell source | ||||
| PTCY | 29 (20-39) | 8 (4-16) | 38 (24-51) | 19 (10-31) |
| ATG | 32 (25-39) | 18 (13-25) | 36 (28-44) | 20 (14-28) |
| P | .41 | .04 | .61 | .72 |
PB, peripheral blood.